期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

树突状细胞疫苗治疗多发性骨髓瘤的研究进展 被引量：4

Dendritic Cell-Based Immunotherapy for Multiple Myeloma——Review
在线阅读 下载PDF
导出
摘要 近年来多发性骨髓瘤的发病率不断上升,但目前对于多发性骨髓瘤仍然没有很好的治疗方法。树突状细胞是一类抗原呈递细胞,具有启动和调控免疫反应的能力。利用肿瘤抗原冲击树突状细胞的免疫治疗策略已被证明是安全的并且对许多肿瘤具有一定的治疗效果。本文综述了多发性骨髓瘤相关的各种肿瘤抗原类型及树突状细胞免疫治疗多发性骨髓瘤的临床实验,并且分析了树突状细胞免疫治疗在未来实验研究方面的前景。 Patients with multiple myeloma （MM） have increased constantly in recent years, but treatment for patients with MM is currently unsatisfactory and it is necessary to develop new complementary therapies. Dendritic cells （DCs） are specialized antigen-presenting cells capable of initiating and regulating immune responses. Vaccination with tumor antigen-pulsed DCs has shown to be safe and possesses therapeutic effect against many tumors. In this review, the various types of MM-associated antigens and clinical trials on DC-based immunotherapy in MM are summarized, the development of DC immunotherapy for MM patients in future trials is discussed.
作者 朱学军 何龙 孙雪梅
机构地区 江苏省中医院血液科
出处 《中国实验血液学杂志》 CAS CSCD 2009年第3期821-825,共5页 Journal of Experimental Hematology
关键词 多发性骨髓瘤 树突状细胞 免疫治疗 multiple myeloma dendritic cell immunotherapy
分类号 R733.3 [医药卫生—肿瘤] R730.51 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1Wang S,Hong S,Wezeman M,et al.Dendritic cell vaccine but not idiotype-KLH protein vaccine primes therapeutic tumor-specific immunity against multiple myeloma.Front Biosci,2007, 12:3566-3575
  • 2Van de-Velde AL,Berneman ZN,Van Tendeloo VF.Immunotherapy of hematological malignancies using dendritic cells.Bull Cancer,2008, 95:320-326
  • 3Hundemer M,Schmidt S,Condomines M,et al.Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.Exp Hematol,2006,34:486-496
  • 4Rew SB,Peggs K,Sanjuan I,et al.Generation of potent antitumor CTL from patients with multiple myeloma directed against HM1.24.Clin Cancer Res,2005 , 11:3377-3384
  • 5Qian J,Xie J,Hong S,et al.Dickkopf-1 (DKK1) is a widely expressed and potent tumor-associated antigen in multiple myeloma.Blood,2007, 110:1587-1594
  • 6Dadabayev AR,Wang Z,Zhang Y,et al.Cancer immunotherapy targeting Sp17:when should the laboratory findings be translated to the clinics? Am J Hematol,2005 , 80:6-11
  • 7丁岩松,陈文明.负载U266细胞抗原的树突状细胞诱导T细胞的抗骨髓瘤活性[J].中国实验血液学杂志,2007,15(3):581-585. 被引量：2
  • 8Lee JJ,Choi BH,Kang HK,et al.Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates.Leuk Lymphoma,2007 , 48:2022-2031
  • 9Hayashi T,Hideshima T,Akiyama M,et al.Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.Blood,2003 ,102:1435-1442
  • 10Vasir B,Borges V,Wu Z,et al.Fusion of dendritic eels with multiple myeloma cells results in maturation and enhanced antigen presentation.Br J Haematol,2005 , 129:687-700

二级参考文献8

  • 1Fields RC,Shimizu K,Mule JJ.Murine dentritic cells pulsed with whole tumor lysates mediates potent antitumor immune responses in vitro and in vivo.Proc Natl Acad Sci USA,1998;95:9482-9487
  • 2Reichardt VL,Milazzo C,Brugger W,et al.Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells.Haematologica,2003;88:1139-1149
  • 3Wen YJ,Min R,Tricot G,et al.Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma:promising effector cells for immunotherapy.Blood,2002;99:3280-3285
  • 4Raje N,Hideshima T,Davies FE,et al.Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.Br J Haematol,2004;125:343-352
  • 5Feuerstein B,Berger TG,Maczek C,et al.Amethod for the production of cryopreserved aliquots of antigen preloaded,mature dendritic cells ready for clinic use.J Immunol Medthod,2000;245:15-29
  • 6Pecher G,Schirrmann T,Kaiser I,et al.Efficient cryopmservation of dendritic cells transfected with cDNA of a tumour antigen for clinical application.Biotechnol Appl Biochem,2001;34:161-166
  • 7Fonteneau JF,Larsson M,Bhardwaj N,et al.Interactions between dead cells and dendritic cells in induction of antiviral CTL responses.Curr Opin Immunol,2002;14:471-477
  • 8VERG Véronique,MARTINACHE Chantal,LEON Anne,GORIN Norbert-Claude,BERNARD Jacky,LOPEZ Manuel.从单核细胞分化的树突状细胞的低温保存及其临床应用(英文)[J].中国实验血液学杂志,2000,8(4):245-250. 被引量：6

共引文献1

同被引文献55

  • 1陈虎,楼晓,江岷,胡亮钉,俞志勇,徐晨,李渤涛,宁红梅,李欲航,冯凯,刘广贤.树突状细胞介导的抗白血病效应的临床研究[J].中国实验血液学杂志,2005,13(3):412-416. 被引量：9
  • 2Areman EM, Loper K. Cellular therapy: principles, methods, and regulations. Bethesda : AABB, 2009:203-394 ;427-472.
  • 3Hipp J, Atala A. Sources of stem cells for regenerative medicine. Stem Cell Rev, 2008, 4( 1 ) :3-11.
  • 4Kaufman DS. Toward clinical therapies using hematopoietic cells derived from human pluripotent stem cells. Blood, 2009, 114 ( 17 ) :3513-3523.
  • 5Muller R, Lengerke C. Patient-specific plufipotent stem cells: promises and challenges. Nat Rev Endocfinol, 2009,5(4) :195- 203.
  • 6Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant, 2008, 41 (2) :193-198.
  • 7Templin C, Kotlarz D, Faulhaber J, et al. Ex vivo expanded hematopoietic progenitor cells improve cardiac function after myocardial infarction : role of beta-catenin transduetion and cell dose. J Mol Cell Cardiol, 2008, 45(3) :394-403.
  • 8Freimark D, Czermak P. CelL-based regeneration of intervertebral disc defects : review and concepts. Int J Artif Organs, 2009, 32 (4) :197-203.
  • 9Giordano A, Galderisi U, Marino IR. From the laboratory bench to the patient' s bedside: An update on clinical trials with mesenchymal stem cells. J Cell Physiol, 2007, 211(I) :27-35.
  • 10Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: Mesenchymal stem cells: Their phenotype, differentiation capacity, immunological features and potential for homing. Stem Cells, 2007, 25:2739-2749.

引证文献4

二级引证文献14

中国实验血液学杂志
2009年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部